515,398 Shares in Akoya Biosciences, Inc. (NASDAQ:AKYA) Purchased by SVB Wealth LLC

SVB Wealth LLC purchased a new position in shares of Akoya Biosciences, Inc. (NASDAQ:AKYA) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 515,398 shares of the company’s stock, valued at approximately $1,180,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new position in Akoya Biosciences during the 4th quarter worth about $28,000. Barclays PLC lifted its position in Akoya Biosciences by 320.9% during the 3rd quarter. Barclays PLC now owns 39,472 shares of the company’s stock worth $107,000 after buying an additional 30,095 shares in the last quarter. GSA Capital Partners LLP lifted its position in Akoya Biosciences by 87.4% during the 3rd quarter. GSA Capital Partners LLP now owns 310,669 shares of the company’s stock worth $845,000 after buying an additional 144,903 shares in the last quarter. Finally, State Street Corp lifted its position in Akoya Biosciences by 4.2% during the 3rd quarter. State Street Corp now owns 453,296 shares of the company’s stock worth $1,233,000 after buying an additional 18,361 shares in the last quarter. Institutional investors and hedge funds own 79.42% of the company’s stock.

Akoya Biosciences Stock Performance

Akoya Biosciences stock opened at $1.63 on Monday. The company has a current ratio of 2.75, a quick ratio of 1.85 and a debt-to-equity ratio of 5.62. Akoya Biosciences, Inc. has a 1 year low of $1.59 and a 1 year high of $6.31. The company has a market cap of $80.80 million, a PE ratio of -1.38 and a beta of 1.23. The company’s 50-day moving average is $2.51 and its two-hundred day moving average is $2.60.

Wall Street Analyst Weigh In

AKYA has been the topic of several research reports. Craig Hallum downgraded shares of Akoya Biosciences from a “buy” rating to a “hold” rating and reduced their price target for the stock from $7.00 to $5.00 in a research report on Friday, November 15th. Canaccord Genuity Group downgraded shares of Akoya Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Finally, Piper Sandler restated an “overweight” rating and set a $3.00 target price (down from $4.00) on shares of Akoya Biosciences in a research report on Tuesday, November 19th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $5.43.

Akoya Biosciences Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.